Audit: QRS - CJC-1295 for Health & Longevity

Audit conducted on 06/08/2026 21:19 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	91
Passed	83
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Spot-checked every populated span against the ER: protocol cells vs ER lines 449–459, time-to-effect vs ER line 508, benefits vs ER lines 151–213, risks vs ER lines 245–335, contraindications vs ER lines 375/409–419, interactions vs ER lines 365–405, monitoring table vs ER lines 536–551, cadence vs ER line 534, qualitative items vs ER lines 555–560.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Hedges carried across, e.g. time_2_sub “From class trial data only; no shorter timeline is credible” mirrors ER line 508; qualitative_item_5 keeps “most likely to reflect expectation” from ER line 559.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications remain absolute (“Pregnancy and breastfeeding”, “Active malignancy, or cancer treated within 5 years”); no interaction was promoted to a contraindication or demoted from one, other than somatropin which the ER itself calls an “absolute contraindication in combination” (line 375).
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gates draw only on ER Key Interactions & Contraindications; benefits and risks draw only on their respective ER sections; no Benefit-Modifying Factors or Risk-Modifying Factors content appears in the gates.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs, author names or years anywhere in the QRS; every drug name in the gates (prednisone, dexamethasone, octreotide, lanreotide, glipizide, glyburide, raloxifene, tamoxifen, semaglutide, tirzepatide, ritonavir, dolutegravir, ibuprofen, naproxen, pseudoephedrine, phenylephrine, ibutamoren, ipamorelin, GHRP-2, sermorelin, somatropin) appears in ER lines 365–405 for the same interaction.
1.6	The QRS does not introduce new attributions.	🟢	No experts, institutions, sponsors, or societies are named anywhere in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s measured, evidence-gap-forward register; the at-a-glance mirrors the ER Conclusion (lines 586–590) in both content and restraint.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified targets and time windows throughout, presented so a reader can act on them, without cheerleading or alarm.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Protocol and monitoring cells state what was studied and what is used, not what the reader must do.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives; the footer disclaimer states the educational framing.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No instances of “recommended”, “should”, “advise”, or “we suggest” anywhere in the document.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	Grep for “you”/”your” over the whole file returns no matches.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms used are those the ER itself uses and are load-bearing at this compression (arthralgia, paresthesia, HOMA-IR, ApoB); no jargon is introduced that the ER does not carry.
2.8	Information is presented in a concise and very compact manner	🟢	Every list item is a noun phrase or short clause; no item carries a mechanism, citation, or effect size.
2.9	It DOES NOT address the reader directly	🟢	Confirmed as for 2.6 — no second-person address anywhere in the file.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional-range biomarker targets, DEXA scanning, and a 14-marker panel presuppose exactly this audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Monitoring cadence spanning quarterly bloods, weekly blood-pressure checks, and 6-monthly imaging is presented without hedging on burden.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplified or generalist framing; the sheet assumes lab access and self-directed titration.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The speculative risk “adverse effect on long-term mortality” and the untested-benefit framing in the at-a-glance are the longevity-specific signals, carried from ER lines 333–335 and 586–590.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not occur anywhere in the file; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“injection”, “subcutaneous”, “adverse”, “gray-market” used in the ER’s own register; no colloquialisms.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All present verbatim at lines 446, 492, 541, 570, 589, 618, 648, 652–654, 827 and in the four tier <strong> labels of both the benefits and risks cards.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 distinct template variable names are present; the repeating marker_#_* and qualitative_item_# placeholders are correctly expanded to 14 and 6 instances.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Normalized structural diff against the template shows the head/CSS block identical apart from page_title, and <span website="evidence_review">, <span website="audit">, <span website="full_review"> unchanged at lines 423, 426, 440.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section that maps to a QRS region is empty; every tier, gate, and table has source content.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels “The gray-market protocol (drug affinity complex form)”, “Single versus split dosing”, “Best time of day” match ER lines 451, 459, 457; all six qualitative bold labels match ER lines 555–560 verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Biomarker names match the ER table’s first column exactly, including “PSA — men only”, “Lipid panel with ApoB”, “TSH with free T4”, “DEXA body composition scan”.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji in the file; the ER’s ⚠️ “Conflicted” markers on three items were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to the floor permitted by the mandatory-coverage items (8.2, 9.2, 14.2, 15.2): tier entries are bare noun phrases, gate items are drug names plus their required parentheticals, monitoring “Why” cells are five-to-eight-word clauses. No section was expanded rather than condensed.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14; <!doctype html> is line 1 and nothing intervenes.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13, with the descriptive text on line 2 preceding it.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed entirely in an HTML comment; none of its values are duplicated in the header or footer except header_subline_date/header_subline_model, which are their own template variables.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly, because it contains a colon; all other values are bare and untrimmed of nothing.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: cjc_1295_2026-0806-1634_Opus_ER.md, matching the ER’s own filename frontmatter value.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the top of QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0806-2022, correct format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version number, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: cjc_1295_2026-0806-1634_Opus_QRS.html, identical to the file’s actual name on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all ten keys including git_user: evipedia-1 and git_issue: 4864; no stray whitespace or quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “CJC-1295 for Health & Longevity - Quick Reference Sheet”; ER canonical_topic is “CJC-1295 for Health & Longevity” and the ampersand is entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “CJC-1295 for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “08/06/2026”, the correct MM/DD/YYYY rendering of qrs_creation_date: 2026-0806-2022.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header block (lines 415–428) is byte-identical to the template apart from the two variable spans; the ER’s alternate_names list does not appear.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses all three paragraphs of ER lines 586–590: what it is, that the hormone rise is real, that the downstream benefits are untested, and the halted development plus unmeasured long-term safety.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	“one injection works for days” ← line 586; “reliably raises growth hormone and its downstream messenger” ← line 586; “fat, sleep, or thinking benefits sought is untested” ← line 586; “trial death never fully explained” and “long-term safety is unmeasured” ← line 588.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms at all; IGF-1 is rendered as “its downstream messenger” and GHRH as “the brain signal that tells the pituitary gland to release growth hormone”.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	“a trial death” is referenced generically, with no trial name, NCT identifier, year, or sample size.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers of any kind appear in the at-a-glance text.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All twelve items trace to ER lines 409–419 (“Populations who should avoid this intervention”) plus line 375 for the somatropin combination.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All eleven “avoid” bullets from ER lines 409–419 are present, plus the ER’s stated absolute contraindication in combination with somatropin (line 375).
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 573–584: twelve discrete <li> elements inside the stop_items span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER rationale clause after the em-dash was stripped, e.g. “— absolute contraindication given the mitogenic mechanism and the IGF-1-cancer associations” (line 409) does not appear. No item carries a trailing dash clause.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“(HbA1c above 8.0%)”, “NYHA Class III or IV”, “within 90 days”, “Child-Pugh Class B or C”, “(typically under 18–21 years)” all retained; only the purely explanatory glosses (the NYHA and Child-Pugh definitions) were trimmed.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	The ER uses no ranking symbols in these bullets; the QRS accordingly carries none, and multi-part items such as “Myocardial infarction within 90 days, unstable angina, uncontrolled arrhythmia” are plain comma-separated lists.
8.7	If no [stop_items] are present the section is left empty	N/A	Twelve stop items are present.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seventeen items trace to ER lines 365–405 across the prescription, over-the-counter, supplement, and other-intervention subsections.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All eighteen ER interaction bullets are represented except recombinant human growth hormone (line 375), correctly excluded because it appears as a contraindication in the stop gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 592–608: seventeen discrete <li> elements inside the caution_items span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s “— caution, high clinical relevance”, “— absolute pharmacological antagonism”, “— monitor, analytical interference rather than pharmacological” and every Consequence/Mitigation sentence are stripped; no item carries a dash clause.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every ER bullet that carries a drug list retains one, trimmed to two or three exemplars for the page budget (e.g. glucocorticoids keeps prednisone and dexamethasone; GHRPs keeps ipamorelin, GHRP-2, sermorelin); none is dropped entirely.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	No ranking symbols occur in the ER interaction bullets, and all parenthetical drug lists in the QRS are plain comma-separated.
9.7	If no [caution_items] are present the section is left empty	N/A	Seventeen caution items are present.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	The three cells map to ER Therapeutic Protocol lines 451, 459, and 457 respectively.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose and schedule, single-versus-split administration, and timing of day are the three decisions a reader must actually make; the ER’s remaining bullets are background, comparative, or modifier content.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies well more than three actionable aspects and all three sets are populated.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans populated; the values (“1–2 mg weekly”, “Two half-doses, 3–4 days apart”, “Bedtime”) and subs are traceable to ER lines 449–459.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	ER line 508 names exactly three timelines — hormone rise at 24–48 hours, subjective sleep/recovery within two weeks, body composition at 12–26 weeks — and all three are carried.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Hormone rise (the sole High-tier benefit) first, body composition (Medium-tier visceral fat) second, sleep and recovery (Low-tier) third.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct time-to-effect aspects exist in the ER and all three sets are populated.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated; “24–48 hours”, “12–26 weeks”, “First two weeks” and their subs all appear in ER line 508.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information (line 508), so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All eleven entries correspond one-to-one with the ER benefit headings at lines 151–213, tier for tier.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated at lines 543–563.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is a bare noun phrase; none of the ER’s Magnitude figures (15.4%, 7.4%, 4.1 percentage points, P values) or tesamorelin/class attributions appear.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses occur in any benefits entry; the ER’s ⚠️ “Conflicted” flag on “Enhanced Deep Sleep” is also stripped.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers have items in the ER and all four are populated.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All fifteen entries correspond one-to-one with the ER risk headings at lines 245–335, tier for tier.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated at lines 620–642.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is a bare noun phrase; none of the ER’s hazard ratios, confidence intervals, cohort sizes, or antibody percentages appear.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses occur in any risks entry; the ER’s ⚠️ “Conflicted” flags on the glucose-tolerance and cardiovascular items are also stripped.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers have items in the ER and all four are populated.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Marker names, targets, and rationales all trace to the ER Monitoring Protocol & Defining Success table at lines 536–551.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All fourteen ER table rows are present in order: IGF-1, IGFBP-3, fasting glucose, fasting insulin, HOMA-IR, HbA1c, lipid panel with ApoB, hs-CRP, PSA, TSH with free T4, prolactin, morning cortisol, blood pressure, DEXA.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 816–821 reproduce ER line 534: core panel at weeks 6 and 12 then quarterly and 4 weeks after stopping, full panel at 6 and 12 months, weekly blood pressure and weight for 8 weeks then monthly, imaging at baseline and 6 months.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items trace to the ER’s “Qualitative markers” bullets at lines 555–560.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six are present in ER order: sleep quality and depth, recovery between training sessions, joint comfort and hand symptoms, ring and shoe fit, skin texture and healing speed, energy and cognitive clarity.

Issues 06/08/2026 21:19

Pass rate 100.00%. No issues found.

Issues 06/08/2026 21:11

1. 8.5 / 1.3 — Contraindication severity qualifiers dropped: Three [stop_items] broaden the ER’s contraindications by dropping severity/type qualifiers: “uncontrolled arrhythmia” became “arrhythmia” (line 578), “Acute critical illness, major surgery, or acute respiratory failure” became “Critical illness, major surgery, respiratory failure” (line 579), and “diabetic retinopathy” became “retinopathy” (line 575).

Fixes 06/08/2026 21:11

1. 8.5 / 1.3 — Contraindication severity qualifiers restored: Restored the ER’s qualifiers in [stop_items] — “arrhythmia” → “uncontrolled arrhythmia”, “Critical illness, major surgery, respiratory failure” → “Acute critical illness, major surgery, acute respiratory failure”, and “Proliferative or severe non-proliferative retinopathy” → “Proliferative or severe non-proliferative diabetic retinopathy”.

Issues 06/08/2026 21:00

1. 4.5 — Sheet overruns the one-page budget: Visible content totals ~6,950 characters (~969 words), roughly twice what the A4 print box allows; the Key Interactions gate (17 items, lines 592–610), the Contraindications gate (12 items, lines 573–586), and the 14-row Monitoring table with its cadence paragraph (lines 660–824) each carry full ER wording rather than a condensed form.

Fixes 06/08/2026 21:00

1. 4.5 — Decision gates condensed: Trimmed all 12 Contraindications and all 17 Key Interactions to their shortest faithful form (e.g. “Known or suspected pituitary adenoma, or history of pituitary tumour” → “Known, suspected, or prior pituitary adenoma”; example drug lists reduced from three or more names to two, as permitted by 8.5 / 9.5), with no item dropped.

2. 4.5 — Monitoring table shortened: Rewrote every “Why” cell and several “Target” cells in compressed form (e.g. “Earliest warning of the main metabolic risk; more sensitive than glucose” → “Earliest warning of insulin resistance”), keeping all 14 biomarkers and all thresholds intact.

3. 4.5 — Protocol and Time-to-Effect subs tightened: Removed restated values and redundant clauses from the six sub cells (e.g. time_1_sub dropped the “rises within 24–48 hours” duplication of its own value cell).

4. 4.5 — Benefits, Risks, cadence, and Qualitative items compressed: Converted noun phrases to shorter forms (“Reduction in visceral abdominal fat” → “Reduced visceral abdominal fat”), stripped redundant wording from the cadence paragraph and the six qualitative entries. Total visible text reduced from ~6,950 to ~5,947 characters (969 → 827 words).

Issues 06/08/2026 20:51

1. 4.5 — Sheet overflows one A4 page: At the template’s 800px sheet width the content renders to roughly twice the usable height of an A4 page, because the Monitoring targets and rationales (lines 665–815), the Protocol and Time-to-effect sub cells (lines 456–537), the cadence paragraph (lines 821–827) and the Qualitative Assessment items (lines 836–871) reproduce ER prose almost verbatim instead of being condensed to the per-section budget.

Fixes 06/08/2026 20:51

1. 4.5 — Condensed to the one-page budget: Trimmed the four regions that carried near-verbatim ER prose — the three Protocol and three Time-to-effect sub cells, all fourteen Monitoring target/why cells, the cadence paragraph, and three Qualitative Assessment items — and shortened six Contraindication items (e.g. “Recent myocardial infarction (within 90 days), unstable angina, or uncontrolled arrhythmia” → “Myocardial infarction within 90 days, unstable angina, uncontrolled arrhythmia”). All fourteen biomarkers, all six qualitative markers, all twelve contraindications, all seventeen interactions and every parenthetical qualifier and drug list were retained.

Issues 06/08/2026 20:48

1. 13.3 — Qualifiers and mechanism in risk items: “Acromegaly-like tissue changes with chronic supraphysiological use” and “adverse effect on long-term mortality through sustained growth signalling” (QRS lines 644–646) carry a usage qualifier and a mechanistic explanation, and “tachyphylaxis and attenuated response over time” (line 638) appends a restatement of the term itself.

Fixes 06/08/2026 20:48

1. 13.3 — Speculative risk qualifiers stripped: Changed “Acromegaly-like tissue changes with chronic supraphysiological use; adverse effect on long-term mortality through sustained growth signalling” to “Acromegaly-like tissue changes; adverse effect on long-term mortality”, removing the usage qualifier and the mechanistic explanation.
2. 13.3 — Redundant restatement in low-tier risk: Changed “tachyphylaxis and attenuated response over time” to “tachyphylaxis”, dropping the appended restatement of the term.

Issues 06/08/2026 20:40

1. 4.2 / 4.3 — Protocol label abbreviated: action_1_label at line 450 reads “Gray-market protocol”, whereas the ER’s bold label at line 451 is “The gray-market protocol (drug affinity complex form)”; the leading article and the form-identifying parenthetical were dropped.

Fixes 06/08/2026 20:40

1. 4.2 / 4.3 — Protocol label restored verbatim: action_1_label changed from “Gray-market protocol” to the ER’s bold label “The gray-market protocol (drug affinity complex form)”, and the now-redundant lead-in “For the drug affinity complex form:” was removed from action_1_sub, which now opens “A flat 1–2 mg subcutaneously once or twice weekly, often split into two 1 mg doses.”

Issues 06/08/2026 20:33

1. 9.5 — Oral estrogen examples dropped: The Key Interactions item at line 599 reads “Oral estrogens and selective estrogen receptor modulators (raloxifene, tamoxifen)”, dropping the ER’s own example list “(conjugated equine estrogens, oral estradiol)” from ER line 371 entirely rather than trimming it.

Fixes 06/08/2026 20:33

1. 9.5 — Oral estrogen examples restored: Changed the Key Interactions item from “Oral estrogens and selective estrogen receptor modulators (raloxifene, tamoxifen)” to “Oral estrogens (conjugated equine estrogens, oral estradiol) and selective estrogen receptor modulators (raloxifene, tamoxifen)”, reinstating the ER’s example drug list.

Issues 06/08/2026 20:26

1. 4.2 / 4.3 — Protocol cell labels not from ER: [action_1_label] is “Dose”, which matches no ER bold label (its source bullet is “The gray-market protocol (drug affinity complex form):”, ER line 451) and additionally presents a gray-market figure as the canonical dose; [action_2_label] is “Split dosing”, an abbreviation of the ER’s “Single versus split dosing:” (ER line 459).

Fixes 06/08/2026 20:26

1. 4.2 / 4.3 — Protocol cell labels aligned to ER: [action_1_label] changed from “Dose” to “Gray-market protocol” and [action_2_label] from “Split dosing” to the ER’s verbatim “Single versus split dosing”; [action_1_sub] was reworded to “For the drug affinity complex form: …” to avoid repeating the new label.